Abstract:Background: Despite encouraging results from immunotherapy combined with targeted therapy for hepatocellular carcinoma (HCC), the prognosis remains poor. Chemokines and their receptors are an essential component in the development of HCC, but their significance in HCC have not yet been fully elucidated. We aimed to establish chemokine-related prognostic signature and investigate the association between the genes and tumor immune microenvironment (TIME). Methods: 342 HCC patients have screened from the TCGA cohort. A prognostic signature was developed using least absolute shrinkage and selection operator regression and Cox proportional risk regression analysis. External validation was performed using the LIHC-JP cohort deployed from the ICGC database. Single-cell RNA sequencing (scRNA-seq) data from the GEO database. Two nomograms were developed to estimate the outcome of HCC patients. RT-qPCR was used to validate the differences in the expression of genes contained in the signature. Results: The prognostic signature containing two chemokines-(CCL14, CCL20) and one chemokine receptor-(CCR3) was successfully established. The HCC patients were stratified into high- and low-risk groups according to their median risk scores. We found that patients in the low-risk group had better outcomes than those in the high-risk group. The results of univariate and multivariate Cox regression analyses suggested that this prognostic signature could be considered an independent risk factor for the outcome of HCC patients. We discovered significant differences in the infiltration of various immune cell subtypes, tumor mutation burden, biological pathways, the expression of immune activation or suppression genes, and the sensitivity of different groups to chemotherapy agents and small molecule-targeted drugs in the high- and low-risk groups. Subsequently, single-cell analysis results showed that the higher expression of CCL20 was associated with HCC metastasis. The RT-qPCR results demonstrated remarkable discrepancies in the expression of CCL14, CCL20, and CCR3 between HCC and its paired adjacent non-tumor tissues. Conclusion: In this study, a novel prognostic biomarker explored in depth the association between the prognostic model and TIME was developed and verified. These results may be applied in the future to improve the efficacy of immunotherapy or targeted therapy for HCC.

Chemokine-Like Factor-Like Marvel Transmembrane Domain-Containing Family In Hepatocellular Carcinoma: Latest Advances

Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer

Research insights into the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM): their roles in various tumors

Cancer Research Advance in CKLF-like MARVEL Transmembrane Domain Containing Member Family (Review).

Comprehensive Analysis of the Prognosis for Chemokine-Like Factor MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma

CMTM family proteins 1–8: roles in cancer biological processes and potential clinical value

Research advances in CKLF-like MARVEL transmembrane domain containing member 5]

Research Advances in CKLFSF-like MARVEL Transmembrane Domain Containing Member 3.

Bioinformatics-Based Discovery of CKLF-Like MARVEL Transmembrane Member 5 As a Novel Biomarker for Breast Cancer.

Chemokine-like Factor-Like MARVEL Transmembrane Domain-Containing Family in Autoimmune Diseases

Research Advances in Chemokine-like Factor Super Family Member 8

CMTM7 shapes the chronic inflammatory and immunosuppressive tumor microenvironment in hepatocellular carcinoma as an M2 macrophage biomarker

CMTM6, a potential immunotherapy target

CMTM5 is Downregulated and Suppresses Tumour Growth in Hepatocellular Carcinoma Through Regulating PI3K-AKT Signalling

Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma

Functions of CXC Chemokines As Biomarkers and Potential Therapeutic Targets in the Hepatocellular Carcinoma Microenvironment

Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression

Expression of CMTM3 and CMTM5 in clear cell renal cell carcinoma and its significance

P85 CHOLANGIOCARCINOMA (CCA) EXPRESS CHEMOKINE RECEPTOR CXCR7: IMPORTANT ROLE OF CXCR7 IN MEDIATING CXCL12 INDUCED CCA CELLS CHEMOTAXIS AND SURVIVAL

Chemokines and Their Receptors Play Important Roles in the Development of Hepatocellular Carcinoma.

CMTM6 Promotes Hepatocellular Carcinoma Progression Through Stabilizing Β-Catenin.